PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer

Polybromo-1 (PBRM1) gene is a promising biomarker for immunotherapy in clear cell renal cell carcinoma. But to our knowledge, the frequency and clinical relevance of PBRM1 mutation in lung cancer remain unknown. We conducted a retrospective study to evaluate the prevalence of PBRM1 mutation and its...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Huaqiang, Liu, Jiaqing, Zhang, Yaxiong, Huang, Yan, Shen, Jiayi, Yang, Yunpeng, Fang, Wenfeng, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075870/
https://www.ncbi.nlm.nih.gov/pubmed/32195359
http://dx.doi.org/10.1038/s41698-020-0112-3
Descripción
Sumario:Polybromo-1 (PBRM1) gene is a promising biomarker for immunotherapy in clear cell renal cell carcinoma. But to our knowledge, the frequency and clinical relevance of PBRM1 mutation in lung cancer remain unknown. We conducted a retrospective study to evaluate the prevalence of PBRM1 mutation and its correlation with preliminary response to immunotherapy in non-small cell lung cancer (NSCLC). Our results indicated that PBRM1 mutation was more likely to be a negative predictive biomarker for immunotherapy in NSCLC.

Ejemplares similares